• Very preterm infants (<33 weeks)

• Very low birth weight infants

Our team aims to reduce the incidence of chronic lung disease (CLD) in preterm infants through a preventive, minimally invasive, personalized, and longitudinal care model. By integrating standardized respiratory protocols, minimally invasive surfactant therapy (MIST), objective extubation assessment tools, and multidisciplinary collaboration, we effectively shorten invasive ventilation duration and reduce lung injury. Post-discharge care is strengthened through cloud-based home-visiting systems and AI-assisted neurodevelopmental prediction models. This comprehensive approach has consistently achieved CLD rates below national averages and comparable to international benchmarks, establishing a leading neonatal respiratory care model in Taiwan.

• MIST combined with non-invasive ventilation

• Standardized extubation assessment protocol

• Cloud-based follow-up with AI prediction

• ~50 preterm infants per year

• 31 MIST cases completed

• Follow-up until 2 years CA

• CLD rate below national average

• 6% re-intubation after MIST

• 17% extubation failure rate

• Zero mortality with MIST

• Zero severe IVH with MIST

• No major respiratory events

• 90% parental satisfaction

• High communication ratings

• Strong care trust level

• 11 SCI publications

• AsianNeo collaboration

• Benchmarked with Japan

• Established low-risk CLD care model

• Reduced long-term medical burden

• Enhanced Taiwan’s global NICU profile